To further confirm miR-10b/CADM2 regulates EMT process via regulating AKT pathway, we treated HCC cells with a PI3K inhibitor, LY294002 (20 μmol/L) to block PI3K/AKT signaling. This evidence concerns the gene CADM2 and hepatocellular carcinoma.